A combination of homogeneous wall thickness and superior cosmetic quality is offered from Clareo vials from SGD Pharma, which for moulded glass Type II is distinctive in the market. The new range offers technical characteristics similar to the vials in the existing range and can replace them without any regulatory change. Once again, SGD Pharma demonstrates with Clareo its expertise in the control of manufacturing process of moulded glass.
The mission of SGD Pharma, a leading manufacturers of glass containers for primary pharmaceutical packaging, is to improve and protect patients' health by supplying high quality, reliable and innovative glass primary packaging to customers in the pharmaceutical industry. Its commitment is to continuously innovate and to reinforce patient safety by improving the physical, chemical and cosmetic properties of our different types of glass.
The mechanical resistance to shock of the Clareo vials has been considerably improved by obtaining a more homogeneous distribution of the glass (+15pts compared to the standard process). This increased regularity allows a significant reduction of the breakage rate (up to 10x lower).
Clareo vials have more flat and uniform bottoms, which ease the thermal transfer during freeze-drying processes.
Clareo vials also offer a superior cosmetic quality, leading to an improved inspectability before and after filling. Pharmaceutical and biotechnology companies benefit from this advantage, allowing a reduction of their Total Cost of Ownership (TCO), mostly for high value-added products.
Furthermore, customers looking for a more economical alternative to converting Type I glass can find a more affordable solution in Clareo. SGD Pharma can share a list of molecules, for which compatibly with glass Type II has been approved by the authorities.
SGD Pharma is able to supply vials for injectable solutions in molded glass Type II, offering the combined benefits of transparency and strength.
Clareo is available in capacities of 20, 50 and 100ml in Type II and further developments are in progress. Clareo can also be available, on request, in Type III.